58 results
8-K
EX-10.4
TARA
Protara Therapeutics Inc
5 Apr 24
Entry into a Material Definitive Agreement
8:14am
statement filed by the Company prior to the date of this Agreement.
2.3 Expenses. All expenses incident to the Company’s performance of or compliance … comfort letters required by or incident to such performance), (v) Securities Act liability insurance or similar insurance if the Company so desires
8-K
EX-99.4
TARA
Protara Therapeutics Inc
5 Apr 24
Entry into a Material Definitive Agreement
8:14am
) to succeed + Est. Annual US incident HG/HR population (1,3) of 27,000 patients = 1. SEER Bladder Cancer Facts, estimated from 2020 figures. 2
8-K
EX-99.2
99lx6h7dton69e5tt
23 Apr 21
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
7:01am
8-K
EX-99.1
4qf8xs4q
11 Feb 21
Corporate Presentation February 2021
8:01am
8-K
EX-1.1
c7ae wcgo
23 Sep 20
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
9:08am
8-K
EX-1.2
wwu7rzfj a0big
23 Sep 20
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
9:08am